VIJAY AGGARWAL - Corporate Board Profile

INTERPACE BIOSCIENCES, INC.

Filing Date	Source Excerpt
2022-09-20	Dr. Vijay Aggarwal was designated as a director by Ampersand as holder of Series B Preferred Stock, and thereby appointed and elected as a director effective February 1, 2022... Dr. Aggarwal serves as Chair of the Board’s Compliance and Regulatory Committee ("Regulatory Compliance Committee")... and as a member of the Board’s Nominating Committee.
2023-09-22	Dr. Vijay Aggarwal was designated as a director by Ampersand 2018 Limited Partnership, a fund managed by Ampersand Capital Partners ("Ampersand"), as a holder of the Company27s Series B Preferred Stock, and thereby appointed and elected as a director effective February 1, 2022, replacing Eric B. Lev as designee of Ampersand. Dr. Aggarwal serves as Chair of the Board27s Compliance and Regulatory Committee ("Regulatory Compliance Committee") which was formerly part of the Company27s Audit Committee and was formed in January 2020 and as a member of the Board27s Nominating Committee. Currently CEO of Phase Forward Technologies, and formerly a Managing Partner of The Channel Group, Dr. Aggarwal provides strategic advisory and capital formation services to companies with operations or investments in the clinical diagnostics, molecular diagnostic, and anatomic pathology sectors. He is also an active investor in early-stage medical technology companies. Prior to The Channel Group, he served as CEO of Vaxigenix, a pharmaceutical company developing vaccine treatments for colorectal cancer. From 2004-2009, Dr. Aggarwal was President and CEO of Aureon Laboratories, Inc., a predictive pathology company offering advanced tissue analysis services to practicing physicians and the pharmaceutical industry. From 2001 to 2004, he served as President of AAI Development Services, Inc., a global contract research and development services company serving the pharmaceutical and biotech industries. In 1999, following the acquisition of SmithKline Beecham Clinical Laboratories by Quest Diagnostics, Dr. Aggarwal led the team that planned the integration of the two companies and served on the Chairman27s Council. In addition, he served as President of Quest Diagnostic Ventures, where his responsibilities included new technology, new business models, clinical trials testing, and direct20to20consumer strategies. Dr. Aggarwal spent 14 years with SmithKline Beecham Clinical Laboratories ("SBCL"), the clinical laboratory operations of SmithKline Beecham plc. During his tenure with SBCL, he held many positions, including Director of Business Development, Executive Vice President of Laboratories, having direct responsibility for all of SBCL27s U.S.-based laboratories, and as Vice President of Managed Care, responsible for third party reimbursement. Early in his career, Dr. Aggarwal spent 8 years at Bio Science Laboratories, finishing his time with the company as Manager of Toxicology and Special Chemistry. He currently holds Board positions at Accugenomics, Allergenis, Moleculera and Slone Partners. Previous Board positions include Hycor Biomedical, Targeted Diagnostics and Therapeutics and ViraCor IBT Laboratories. He earned a BA in Chemistry from Case Western Reserve University and a Ph.D. in Pharmacology/Toxicology from the Medical College of Virginia. Dr. Aggarwal brings extensive leadership in clinical diagnostic services as well as institutional and individual investment experience.
2024-09-20	Dr. Vijay Aggarwal was designated as a director by Ampersand 2018 Limited Partnership, a fund managed by Ampersand Capital Partners ("Ampersand"), as a holder of the Companys Series B Preferred Stock, and thereby appointed and elected as a director effective February 1, 2022, replacing Eric B. Lev as designee of Ampersand. Dr. Aggarwal serves as Chair of the Boards Compliance and Regulatory Committee ("Regulatory Compliance Committee") which was formerly part of the Companys Audit Committee and was formed in January 2020 and as a member of the Boards Nominating Committee. Currently CEO of Phase Forward Technologies... The following table presents information relating to total compensation for our non-employee directors for the year ended December 31, 2023. Mr. Burnell, our President, Chief Executive Officer and Chairman, does not receive compensation for his services on the Board... Vijay Aggarwal 50,000 - 50,000